寄生虫来源的rOv-ASP-1是一种有效的节省抗原的CD4+ T细胞依赖性三价灭活流感疫苗佐剂,且在缺乏MyD88通路时仍发挥功能
研究在小鼠中评估寄生虫来源蛋白佐剂rOv-ASP-1联合三价灭活流感疫苗(IIV3)的抗原节省效果与免疫机制。结果显示减少佐剂用量并大幅降低IIV3剂量仍可诱导保护,该保护不依赖IIV3特异性Th1/Th2抗体应答及HAI抗体,但CD4+ T辅助细胞不可或缺。佐剂在注射部位促进趋化因子升高和免疫细胞募集,且保护作用似乎不依赖MyD88信号。
要点
- 减少rOv-ASP-1用量并配合40倍更低剂量的IIV3仍可诱导保护。
- 保护不依赖IIV3特异性Th1/Th2相关抗体应答及HAI抗体,但CD4+ T辅助细胞不可或缺。
- rOv-ASP-1在免疫后4小时增加肌肉趋化因子并募集单核细胞、巨噬细胞和中性粒细胞。
核心结论
- rOv-ASP-1佐剂通过刺激注射部位趋化因子积累和免疫细胞募集增强CD4+ T细胞免疫应答,从而实现IIV3的显著抗原节省。
- rOv-ASP-1佐剂化IIV3疫苗诱导的保护似乎在不依赖MyD88信号的情况下也发挥功能。
研究设计与样本
- 研究为小鼠实验,评估rOv-ASP-1联合三价灭活流感疫苗(IIV3)的抗原节省效果与免疫机制。
主要发现
- 减少rOv-ASP-1用量并配合40倍更低剂量的IIV3仍可诱导保护。
- rOv-ASP-1佐剂化IIV3疫苗的效力不依赖IIV3特异性Th1/Th2相关抗体应答,也不依赖HAI抗体的存在。
- CD4+ T辅助细胞对保护不可或缺。
- 免疫后4小时,rOv-ASP-1无论是否联合IIV3均使肌肉中多种趋化因子水平升高,并显著诱导单核细胞、巨噬细胞和中性粒细胞募集至肌肉。
- 募集的单核细胞表面活化标志物MHCII以及CXCR3和CCR2(分别为IP-10和MCP-1的受体)表达更高。
局限性
- 未来研究将尝试阐明rOv-ASP-1佐剂化IIV3疫苗发挥作用的确切机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccination remains the most cost-effective biomedical approach for controlling influenza disease. In times of pandemics, however, these vaccines cannot be produced in sufficient quantities for worldwide use by the current manufacturing capacities and practices. What is needed is the development of adjuvanted vaccines capable of inducing an adequate or better immune response at a decreased antigen dose. Previously we showed that the protein adjuvant rOv-ASP-1 augments influenza-specific antibody titers and survival after virus challenge in both young adult and old-age mice when administered with the trivalent inactivated influenza vaccine (IIV3). In this study we show that a reduced amount of rOv-ASP-1, with 40-times less IIV3 can also induce protection. Apparently the potency of the rOv-ASP-1 adjuvanted IIV3 vaccine is independent of the IIV3-specific Th1/Th2 associated antibody responses, and independent of the presence of HAI antibodies. However, CD4+ T helper cells were indispensable for the protection. Further, rOv-ASP-1 with or without IIV3 elicited the increased level of various chemokines, which are known chemoattractant for immune cells, into the muscle 4 h after immunization, and significantly induced the recruitment of monocytes, macrophages and neutrophils into the muscles. The recruited monocytes had higher expression of the activation marker MHCII on their surface as well as CXCR3 and CCR2; receptors for IP-10 and MCP-1, respectively. These results show that the rOv-ASP-1 adjuvant allows substantial antigen sparing of IIV3 by stimulating at the site of injection the accumulation of chemokines and the recruitment of immune cells that can augment the activation of CD4+ T cell immune responses, essential for the production of antibody responses. Protection elicited by the rOv-ASP-1 adjuvanted IIV3 vaccine also appears to function in the absence of MyD88-signaling. Future studies will attempt to delineate the precise mechanisms by which the rOv-ASP-1 adjuvanted IIV3 vaccine works.
引用
- Jain S, George PJ, Deng W, et al. The parasite-derived rOv-ASP-1 is an effective antigen-sparing CD4+ T cell-dependent adjuvant for the trivalent inactivated influenza vaccine, and functions in the absence of MyD88 pathway. Vaccine. 2018. PMID: 29764680. doi:10.1016/j.vaccine.2018.05.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。